Sign up to save your podcasts
Or
Share Formulation as Strategy: Why CDMOs Matter More Than Ever
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Formulation as Strategy: Why CDMOs Matter More Than Ever
Episode Title: Formulation as Strategy: Why CDMOs Matter More Than Ever
Guest: Elizabeth Hickman, President & CEO, Austin Pharmaceutics
Episode Overview
In this episode of RealPharma, hosts Nari Oh and Ian Wendt sit down with Elizabeth Hickman, President and CEO of Austin Pharmaceutics, to unpack one of the most critical—and often misunderstood—elements of drug development: formulation and the evolving role of CDMOs.
As drug molecules become more complex and solubility challenges grow, CDMOs are no longer just manufacturing vendors. They are strategic partners helping biotech and pharma companies bridge the gap between discovery and commercialization. Elizabeth shares her journey from commercial pharma leadership to running a science-driven CDMO, and explains why formulation decisions made early can determine whether a promising molecule ever reaches patients.
🔍 Key Topics Covered
The expanding role of CDMOs
Why CDMOs are shifting from executional partners to strategic extensions of pharma and biotech teams.
Why formulation is make-or-break
How solubility and bioavailability challenges derail up to 80% of modern drug candidates—and why these issues must be addressed early.
From “undruggable” to developable
How AI-driven discovery and structure-based drug design are unlocking new targets while creating new development hurdles.
Inside Austin Pharmaceuticals’ approach
A look at Austin’s proprietary Kinetisol® technology and how amorphous solid dispersion can improve bioavailability, scalability, manufacturability, and sustainability.
Small biotech vs. big pharma dynamics
What early-stage companies should look for in a CDMO partner—and the most common mistakes teams make when selecting one.
Patient impact starts with formulation
How pill burden, dosing frequency, and manufacturability directly affect adherence, cost, and competitiveness.
The future of CDMOs
Reshoring, cost pressures, AI adoption, and the growing need for talent with both scientific depth and entrepreneurial mindset.
💡 Memorable Takeaways
“Formulation is where promising molecules either become viable drugs—or stall out.”
Solving in-vivo performance alone isn’t enough; scalability and manufacturability must be designed in from day one.
The best CDMO relationships are built on transparency, urgency, and shared long-term vision.
Advanced formulation isn’t just a technical advantage—it’s a competitive and economic one.
👤 About the Guest
Elizabeth Hickman is President and CEO of Austin Pharmaceutics, a U.S.-based early-phase CDMO specializing in formulation development for challenging small-molecule drugs. With a background spanning commercial strategy, drug launches, and executive leadership, Elizabeth brings a sponsor-centric mindset to CDMO partnerships—helping clients accelerate innovation while reducing risk.
View all episodes
By RealPharma
5
1212 ratings
Episode Title: Formulation as Strategy: Why CDMOs Matter More Than Ever
Guest: Elizabeth Hickman, President & CEO, Austin Pharmaceutics
Episode Overview
In this episode of RealPharma, hosts Nari Oh and Ian Wendt sit down with Elizabeth Hickman, President and CEO of Austin Pharmaceutics, to unpack one of the most critical—and often misunderstood—elements of drug development: formulation and the evolving role of CDMOs.
As drug molecules become more complex and solubility challenges grow, CDMOs are no longer just manufacturing vendors. They are strategic partners helping biotech and pharma companies bridge the gap between discovery and commercialization. Elizabeth shares her journey from commercial pharma leadership to running a science-driven CDMO, and explains why formulation decisions made early can determine whether a promising molecule ever reaches patients.
🔍 Key Topics Covered
The expanding role of CDMOs
Why CDMOs are shifting from executional partners to strategic extensions of pharma and biotech teams.
Why formulation is make-or-break
How solubility and bioavailability challenges derail up to 80% of modern drug candidates—and why these issues must be addressed early.
From “undruggable” to developable
How AI-driven discovery and structure-based drug design are unlocking new targets while creating new development hurdles.
Inside Austin Pharmaceuticals’ approach
A look at Austin’s proprietary Kinetisol® technology and how amorphous solid dispersion can improve bioavailability, scalability, manufacturability, and sustainability.
Small biotech vs. big pharma dynamics
What early-stage companies should look for in a CDMO partner—and the most common mistakes teams make when selecting one.
Patient impact starts with formulation
How pill burden, dosing frequency, and manufacturability directly affect adherence, cost, and competitiveness.
The future of CDMOs
Reshoring, cost pressures, AI adoption, and the growing need for talent with both scientific depth and entrepreneurial mindset.
💡 Memorable Takeaways
“Formulation is where promising molecules either become viable drugs—or stall out.”
Solving in-vivo performance alone isn’t enough; scalability and manufacturability must be designed in from day one.
The best CDMO relationships are built on transparency, urgency, and shared long-term vision.
Advanced formulation isn’t just a technical advantage—it’s a competitive and economic one.
👤 About the Guest
Elizabeth Hickman is President and CEO of Austin Pharmaceutics, a U.S.-based early-phase CDMO specializing in formulation development for challenging small-molecule drugs. With a background spanning commercial strategy, drug launches, and executive leadership, Elizabeth brings a sponsor-centric mindset to CDMO partnerships—helping clients accelerate innovation while reducing risk.
More shows like RealPharma: Conversations with Pharma Pathfinders
View all
Wait Wait... Don't Tell Me!
38,832 Listeners
The NPR Politics Podcast
25,843 Listeners
WSJ What’s News
4,352 Listeners
HBR IdeaCast
169 Listeners
The Daily
112,482 Listeners
Bold Names
1,450 Listeners
It's Been a Minute
9,098 Listeners
The Readout Loud
323 Listeners
Behind the Money
228 Listeners
The Journal.
6,064 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,041 Listeners
BioCentury This Week
34 Listeners
F1 Nation
691 Listeners
SmartLess
58,322 Listeners
Hard Fork
5,529 Listeners